Navigation Links
CTI Receives NASDAQ Letter
Date:9/5/2008

SEATTLE, Sept. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTICD; and MTA: CTIC) announced that today, the Company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC indicating that the Company is not in compliance with the $50,000,000 minimum market value of listed securities requirement set forth in NASDAQ Marketplace Rule 4450(b)(1)(A). Furthermore, the Company does not comply with NASDAQ Marketplace Rule 4450(b)(1)(B), which is an alternative to Rule 4450(b)(1)(A), and requires total assets and revenue of $50,000,000 each for the most recently completed fiscal year or two of the last three most recently completed fiscal years.

If the Company does not regain compliance by October 6, 2008, the Staff will notify the Company that its securities will be delisted. However, the Company may appeal the Staff's determination to delist its securities to a Listing Qualifications Panel. Alternatively, in the event the Company does not believe that it will be able to regain compliance, the Company intends to apply to transfer its securities to the NASDAQ Capital Market, which would continue to allow trading in the Company's securities.

The Company has been provided 30 calendar days, or until October 6, 2008, to regain compliance. The Staff advises that such compliance can be achieved if, at any time before October 6, 2008, the market value of the listed securities of the Company's common stock is $50,000,000 or more for a minimum of 10 consecutive business days.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
2. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
3. ESA Receives 2008 Frost & Sullivan North American Technology Innovation Award for Development of Integrated Metabolomics Systems
4. Moffitt Cancer Center Receives Prestigious SPORE Grant Worth More Than $10 Million
5. Barr Receives Approval for Generic Version of Razadyne(R) Tablets
6. Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay
7. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
8. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
9. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
10. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
11. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... York, NY (PRWEB) May 21, 2013 Bed ... And according to My Cleaning Products, many turn to chemical-based ... because of the health and environmental risks those solutions present, ... with Bed Bug Bully instead. , According to ... bed bugs as they used to be. It shared that ...
(Date:5/21/2013)... 2013 Inflamax scientists worked closely ... to design the study, which will provide critical ... models used in the study of allergy treatments, ... Challenge (NAC) models. Although both the models are ... date no direct comparison between the allergic responses ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... Scientists are using the engineering technology behind the ... models for the replacement of delicate and complex ... The researchers, combining engineering and plastic ... topological optimization to design an experimental 3-D structure ...
... IRVINE, Calif. , July 12 ... the development and commercialization of personalized DNA-based diagnostics ... completed license agreements with key Norwegian cancer researchers. ... promising genomic technologies with the intention of developing ...
... , July 12, 2010 Points to,Novel Pathway for Drug ... Abdominal Aortic Aneurysm, Heart Attack and,PAD , ... Scientists at deCODE genetics and academic ... and North America today,report the discovery of a common ...
Cached Biology Technology:High-performance engineering used to design facial bone replacements 2High-performance engineering used to design facial bone replacements 3OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 2OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 3OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 4deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 2deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 3deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 4
(Date:5/21/2013)... have developed a new method for delivering molecules ... the cell surface. The technique could find applications ... fields. , Bulk electroporation a technique used ... in the cell membrane that are caused by ... increasingly popular method of cell transfection. (Cell transfection ...
(Date:5/21/2013)... the University of Illinois at Chicago College of Medicine will ... fat -- its main energy source -- and how changes ... a new $2 million, 4-year grant from the National Heart, ... how it uses fuel for energy. These changes may play ... are different in men and women, says E. Douglas Lewandowski, ...
(Date:5/21/2013)... of biomass experts , Where? Copenhagen, ... 03-07 June 2013 , Why? ... assessment, market and policy developments, manufacturing and installation, drawing ... benefiting from its 2013 edition from a record of ... countries, more than 240 plenary and oral presentations, more ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Do men's and women's hearts burn fuel differently? 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4
... a gas they also produce naturally as a hormone, the result ... and fading in the case of flowers all of which ... plants with products available in the market today, such as EthylBloc ... for fruits and vegetables, that contain a compound that blocks ...
... mechanism of action of genes has been hampered by the ... is true for even the most common class of cancer-associated ... events in cells by phosphorylating and modulating the activity of ... efforts that up to a quarter of kinases may play ...
... TAMPA, Fla., May 1 Stinger Systems, Inc. ... today announced,that it had reached a settlement agreement ... Inc. said it settled the matter without admitting ... barring future,violations. Stinger Systems, Inc. also said that ...
Cached Biology News:A new idea for how anti-aging products delay ripening of fruit and wilting of flowers 2A new idea for how anti-aging products delay ripening of fruit and wilting of flowers 3
Anti-Tissue Trans-glutaminase (IgA) EIA Sample Size: 10 l...
... a new technology for sensitive detection ... amounts of DNA (5). This process ... modify the DNA, followed by PCR ... distinguish methylated from unmethylated DNA. The ...
... Incubator/Shaker HT is designed for ... Incubator/Shaker HT is ideal for ... and primer extension assays. iEMS ... a one-cabinet model, allowing the ...
... atlantica Description: Beta-Agarase is useful in ... low-melting-temperature agarose. Beta-Agarase digests the agarose ... Friendly Properties: Heat Inactivation: 65C, 15 ... pH: 6.5 Purity: Tested for contaminating ...
Biology Products: